An overview of sex hormones in relation to SARS-CoV-2 infection

Marzieh Saei Ghare Naz1*, Mojdeh Banaei2, Sareh Dashti3 & Fahimeh Ramezani Tehrani*

1Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, 1985714713, Iran
2Mother & Child Welfare Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, 7916613885, Iran
3Department of Midwifery, Mashhad Branch, Islamic Azad University, Mashhad, 9187147578, Iran

*Author for correspondence: fah.tehrani@gmail.com

Aim: Sex differences in COVID-19 outcomes might be explained from a sex hormones (SexHs) perspective.

Materials & methods: PubMed, Scopus, Web of Science, EMBASE and Google Scholar were searched up to March 2021. Results: Based on the literature review, the crosstalk between SexHs (estrogens, progesterone and testosterone), their receptors (estrogen α and β, androgen, and progesterone) and the immune system shaped the sex-related differences in immune responses against COVID-19. Differential production of SexHs over the lifespan (during pregnancy, reproductive years, menopause and andropause) and over different seasons may result in disparities in body response toward COVID-19. Moreover, SexHs-specific differences might affect vaccine efficacy and response to treatment. Conclusion: The roles of SexHs need to be considered in vaccine development and even treatment of COVID-19.

Lay abstract: Female and male sex hormones (SexHs) play a pivotal role in the body’s defense against viral infections. SexHs and their binding molecules are among the main possible indicators of sex disparities in COVID-19 severity and response to treatment. Changes in the levels of SexHs from the childbearing age to menopause and pregnancy in females, and the aging process in males affect the immune function. This article sheds light on how physiologic hormonal differences in different sexes and in different stages of life affect COVID-19 severity. As a consequence the role of SexHs should be considered in vaccine development and treatment of COVID-19, especially for patients who suffer from hormone-related medical conditions in different stages of life.

First draft submitted: 17 March 2021; Accepted for publication: 1 July 2021; Published online: 20 July 2021

Keywords: androgens • COVID-19 • estradiol • female • genes • gonad • male • risk factor • sex specific • sex hormone
It seems that SexHs are among the main factors related to the sex-specific response to COVID-19 [19–21]. To address SexHs in relation to SARS-CoV-2 infection, we have collected and discussed the findings of available literature. A clear understanding of the role of SexHs in COVID-19 development and progression can help design future observational and clinical studies to prevent and treat this disease.

Materials & methods
A narrative review was undertaken in accordance with the scale for the quality assessment of narrative review articles [22]. Electronic databases including PubMed, Scopus, Web of Science, EMBASE, Cochrane Library and Google Scholar were searched for relevant studies up to March 2021.

The search was conducted using the following key terms: ‘gonadal steroid hormones’, ‘hormones, gonadal steroid’, ‘steroid hormones, gonadal’, ‘sex steroid hormones’, ‘hormones, sex steroid’, ‘steroid hormones, sex’, ‘sex hormones’, ‘testosterone’, ‘progesterone’, ‘estradiol’, ‘androgens’, ‘gonad’, ‘ovary’, ‘testis’, ‘severe acute respiratory syndrome coronavirus 2’, ‘2019-ncov’, ‘Wuhan coronavirus’, ‘SARS-CoV-2’, ‘2019 novel coronavirus’, ‘COVID-19 virus’, ‘coronavirus disease 2019 virus’, ‘COVID19 virus’, ‘Wuhan seafood market pneumonia virus’ and ‘2019-nCoV’.

The search was limited to articles written in English. Researchers also performed a manual search in the references of the retrieved articles.

The titles and abstracts of the studies were reviewed for eligibility. The eligibility criteria included studies that investigated the relationship between SexHs and COVID-19. Observational and experimental studies, opinions, commentaries and letters to the editor, review papers, and electronic books which investigated whether SexHs affect the host’s immunity, COVID-19-related gene expression and COVID-19 infection were included in this review.

Results & discussion
The results are presented and discussed in four sections: sex-specific production of SexHs, sex-specific immunoregulatory effects of SexHs, chromosome-linked genes and sex-specific production of SexHs, and SexHs and pre-existing chronic diseases related to hormone disorders in the context of COVID-19.

Sex-specific production of SexHs
Human and animal studies have provided evidence that the levels of SexHs may have multiple effects on lung development and function, the host’s resistance to different parasites, susceptibility to respiratory infections and numerous lung diseases [23–25]. Note that the levels of SexHs can modulate the host’s immune response and respiratory control measures [26,27]. In general, similar SexHs including estrogens, progesterone and testosterone, are produced in male and female bodies, but these hormones have different serum levels, physiological functions, and target tissues in males and females [28,29]. In males, testosterone is mainly produced in testes with the diurnal rhythm; also, a slight amount of estrogens and progesterone is produced in the male body [30–32]. In contrast, in females, estrogens and progesterone are mainly produced in the ovaries in a cyclical pattern, while a slight amount of testosterone is produced by the ovaries and adrenal glands [28,29,33]. Through the developmental process, minimal presentation of SexHs has been shown during infancy; however, with the onset of adolescence, the level of SexHs rises during the reproductive aging, and the cyclic rise and fall of SexHs end by a transition to menopause phase (minimal presentation of estradiol and progesterone) [34]. Indeed, increased levels of SexHs are observed in the critical period of pregnancy [34]. SexHs also contribute to age-specific immune system response; therefore, menopause, andropause and SexH-related changes alter the immune activity [35].

It is evident in a study that, males are more susceptible to respiratory infections in all age groups (childhood and adulthood) than females [23]. This possible variation is explained by variations in the levels of SexHs, anatomic and lifestyle factors [23]. High testosterone levels due to facilitating viral entry could serve a potentially unfavorable role against COVID-19 in males. Surprisingly, the low testosterone levels in males also play an unfavorable role against COVID-19 [36]. In contrast, in females, progesterone and estrogens might show antiviral activity [36]. High 17β-estradiol (E2) and progesterone (P4) levels might improve immune response against COVID-19 [37]. Therefore, SexHs levels may serve as a double-edged sword against COVID-19.

To date, limited evidence exists regarding the effect of COVID-19 on testosterone levels. However, based on the existing evidence, androgen levels might affect ACE2 expression [38,39]. A recent study in Turkey on 44 patients (24 positive and 20 negative for COVID-19) demonstrated that the total testosterone (TT) levels decreased in
patients with COVID-19 pneumonia [40]. A study conducted in 2010 demonstrated that TT was decreased in males with respiratory tract infections [41]. Furthermore, there is evidence that in patients with respiratory tract infections without COVID-19, TT levels were higher than in patients with COVID-19 infection, but both groups had lower levels of TT compared with the control group [42]. A recent cohort study by Dhindsa et al. on 90 males and 62 females with COVID-19 revealed that lower testosterone levels in males were associated with increased severity of COVID-19, inflammatory markers and disease-related mortality [43]. Another study also demonstrated that low TT and calculated free testosterone at admission were associated with poor outcomes [44]. These findings could be explained by the possible role of testosterone in inducing ACE2 as a lung-protective enzyme [45], and testosterone's anti-inflammatory role through increasing cytokines [46,47]. However, the exact underlying mechanism is unknown. Overall, testosterone levels may affect COVID-19 progression and severity through its potential role in the regulation of the immune system or its effect on viral entry and fusion [48].

There is no clear evidence regarding the regeneration of lung tissue after the clearance of COVID-19 infection. Moreover, the role of androgens in repairing and generating lung tissue after damage due to the infection is unclear. It is evident in a study that innate immune cells greatly contribute to repairing the virus-induced inflammation [49], while the androgen and AR play a significant role in the innate and adaptive immune system [50]. In addition, it is well known that androgen is critical in delaying lung maturation during fetal life, by acting on lung fibroblast cells [51]. The exact role of androgens in adult human lung function is not fully understood. Evidence from unrelated studies showed that anti-androgenic therapy by spironolactone was effective in males affected by COVID-19. Importantly, the potential mechanism of anti-androgen treatments, including spironolactone, is accomplished through the anti-inflammatory and antifibrotic effects of these treatments on fibroblasts [52]. On the other hand, there is evidence that ARs exist on the lung fibroblasts [53]. Further studies are required to identify the exact role of androgens on lung fibroblasts.

Numerous studies showed that seasonal variations in the level of SexHs may be observed in both males and females [54,55]. Andersson et al. found that testosterone levels were at the lowest level in males from winter to early spring [55]. Moreover, Bjørnerem et al. found 0.2–0.9% seasonal variation in estradiol in circulation in both males and females which peaked in June and May in postmenopausal women and men, respectively, while the nadir was observed in October in both sexes [54]. It is hypothesized that seasonal change in the levels of SexHs may affect the COVID-19 pandemic in terms of prevention and treatment. Therefore, it is recommended that future studies investigate the role of this variation in COVID-19 vaccine response to improve COVID-19 control.

In terms of the variation in drug reactions, recent data showed that physiological rise and fall in the levels of SexHs throughout the lifespan (aging, puberty and pregnancy) might affect drug response [56]. Therefore, response to treatment in patients with COVID-19 might be affected by SexHs-related factors.

Recently, the effect of SexH therapy has been investigated in COVID-19, and there are ongoing clinical trials to examine the impact of SexHs on COVID-19. Studies have investigated and discussed the possible therapeutic role of spironolactone, an anti-androgenic agent, in COVID-19 [57,58]. Estrogens and progesterone are other candidates against COVID-19 [37]. Considering the important role of SexHs, clinicians and researchers should pay more attention to sex differences in the dose and scheduling of COVID-19 vaccination [59].

In summary, differences in the production of SexHs might lead to a disparity between females and males in terms of dealing with the infection. Note that sex-specific production of SexHs during different life stages might contribute to COVID-19 onset, progression, and even vaccine efficacy and drug response. The role of SexHs should be considered in the design of effective COVID-19 prevention strategies. Future trials are recommended to better understand the risk/benefit of SexHs-based vaccination.

**Sex-specific immunoregulatory effects of SexHs**

SexHs may affect the immune system's response against pathogens [60], and therefore, lead to sex-specific immunoregulatory effects, which can be due to variations in the function and number of B and T lymphocytes, monocytes, granulocyte, natural killer cells, and the production of TNF-α, IL-1β, IFN-γ, and IL-2, IL-4, IL-6, IL-10, IL-12 and IL-18 between sexes [61]. Immune responses vary in humans depending on hormonal variation across reproductive phases [61]. In other words, the levels of SexHs contribute to immune regulation and response in both innate and adaptive immunity [62]. SexH receptors (estrogen receptors α and β, AR, and progesterone receptor) may act as rate-limiting points in immune activity [63]. Testosterone and estrogen act as regulators in immune function [64]. Besides, progesterone and testosterone similarly suppress immunity, both through innate and cell-mediated immune responses [20].
Progesterone suppresses Th1 response and supports the production of Th2 cytokines [20]. Estrogen receptors induce powerful humoral and cellular immune responses [65,66]. Similarly, estrogen was found to contribute to upper and lower airways function [67-69]. Therefore, a cyclic variation has been observed for SexHs during the menstrual cycle, which is found to affect respiratory functions [69].

Female SexHs including estradiol and progesterone, act as a regulator in innate and adaptive immunity [70]. It seems that females can be more resistant to viruses. This finding may be because estrogens can stimulate the immune system by modulating the function of B cells and the production of Th1 pro-inflammatory cytokines and Th2 anti-inflammatory cytokines [61,71,72]. In patients with COVID-19, the virus induces the vascular process in the lungs, while estradiol plays a possible protective role by positively modulating vascular responses [73]. In the same vein, Suba discussed the protective immune response of estrogen against COVID-19 and highlighted its role in preventive and therapeutic approaches [74].

A female’s life stage, based on the reproductive cycle, begins with menstruation and ends with menopause. Based on the evidence, female's reproductive cycle (menstruation, ovulation and pregnancy) affects the immune system [61]. It is well established that dramatic changes in the level of SexHs lead to immune response changes against viral respiratory infections [9]. Therefore, immune-cell count and activity may change during the menstrual cycle because of hormonal fluctuation [75]. Females in the progesterone-dominant phase of the menstrual cycle (mid-luteal phase) are more susceptible to infectious diseases [76]. A case report of two female COVID-19 patients illustrated that the positive results of the reverse transcriptase-PCR (RT-PCR) test during the first menstrual period turned negative after hospitalization in one case, and in another case, the negative RT-PCR test turned positive before hospitalization during the first menstrual period [77]. Furthermore, a cross-sectional study by Ding et al. in China found that estradiol (E2) had an inverse correlation with COVID-19 severity [78]. Moreover, recent reports highlight that pregnant women are more prone to COVID-19 infection because of dramatic changes in SexHs and increased expression of ACE2 during pregnancy [79,80]. Female menopause status also acts as a risk factor for COVID-19 [78]. Endogenous and exogenous estrogens may activate the innate and cell-mediated immune responses, but testosterone and progesterone suppress the immune system [81]. Lung immune cells including dendritic cells, macrophages, neutrophils and eosinophils, are also affected by the expression and function of SexH receptors [82]. Further studies are required to compare different treatment approaches by considering the immunoregulatory effects of SexHs.

There are relevant questions regarding the role of testosterone levels (low/high) in the COVID-19 pandemic [21]. Polycystic ovary syndrome is a common endocrine disorder in women of reproductive age, and is characterized by hyperandrogenism. Higher male SexHs in the polycystic ovary syndrome population may affect their susceptibility to COVID-19 and the severity of COVID-19 outcomes [83]. Recent reports from different countries established that males are more prone to adverse outcomes of COVID-19 [84], even at a similar prevalence of infection in both sexes [6]. Testosterone has a suppressive immune action [85]. It is suggested that vaccines and therapies targeted to increase T cell in males might benefit from an immune response against COVID-19 [86].

In summary, the physiological crosstalk between SexHs and immune cells contributes to releasing cytokines [87]. From a biological point of view, male and female SexHs over the life course also affect the immune response to vaccines [88]. Different immune responses in males and females may result in differences in vaccine effectiveness [89]. Therefore, researchers and clinicians should consider the importance of sex differences in COVID-19 vaccine development [59].

**Chromosome-linked genes & sex-specific production of SexHs**

Both SexH-specific gene expression and SexH alterations contribute to the pathology and immune response to different disorders [90-92]. The X chromosome contains the largest number of immune-associated genes [93]; therefore, double X-chromosomes in females may lead to a more robust immune response. However, the ubiquitous expression of ACE2 may damage reproductive function in females with COVID-19 [94]. ACE2 is highly expressed in testes as an androgen secretion source [95,96], indicating that SARS-CoV-2 may cause testicular dysfunction [97,98]; this effect may disrupt the reproductive capacity in infected men.

ACE2 acts as a host receptor for COVID-19 infection, and ACE2 gene variants may alter the susceptibility to this infection [99]. ACE2 has a sex chromosome-independent activity because its gene is located on the X chromosome [100]. SARS-CoV-2 enters the lungs via the ACE-2 receptor. There is a sex difference in the expression of ACE2 in the lung. It seems that modulation of ACE2 by SexH modulators could potentially be a supportive therapy for COVID-19 patients [101].
Another aspect that needs to be highlighted is that males have the potential to have the homozygous ACE2 gene \(^{[102]}\). In line with the findings mentioned above, Manning and Fink found that a high-digit ratio 2D:4D, which demonstrates high prenatal estrogen or low prenatal testosterone, could act as a possible risk factor for the severity of COVID-19 in males in 41 nations \(^{[103]}\). The possible explanation was related to the inverse correlation between male 2D:4D and the expression of ACE2 \(^{[103]}\).

In summary, SexH-specific gene expression could affect the vaccine-related immune response \(^{[88]}\). Researchers should consider the importance of SexHs fluctuation over the life span.

**SexHs & pre-existing chronic diseases related to hormone disorders in the context of COVID-19**

SexHs imbalance may describe different chronic conditions \(^{[104-106]}\), which act as risk factors for COVID-19 and its poor outcomes. In fact, the fluctuation in SexHs may lead to sex-related differences in susceptibility to diseases, obesity and other factors, which are identified as risk factors for COVID-19 infection. For example, sex differences in leptin, insulin and estrogen play a critical role in the regulation of body weight \(^{[107]}\). SexHs may affect platelet activity and reactivity \(^{[108]}\). The potential role of platelet in COVID-19 has also been reported \(^{[109]}\). Notably, the immunomodulatory effects of SexHs could affect metabolic health \(^{[110]}\). On the other hand, some risk factors including obesity, diabetes, hypertension and various other medical conditions, are associated with poor outcomes in COVID-19 patients \(^{[111,112]}\).

In summary, pre-existing chronic diseases related to hormone disorders may affect the immune response against COVID-19. To achieve the best health outcomes in males and females with pre-existing hormone-related chronic conditions, information should be obtained regarding the best dose selection of vaccines and drugs.

**Conclusion**

COVID-19, a complex viral disease, may present and progress in various forms in male and female bodies. Synthesis, regulation and function of SexHs in two hormonal conditions (physiological hormonal changes during the lifespan, hormonal disorders and developing pre-existing chronic diseases) are linked to immune responses to COVID-19. SexH fluctuations during the lifespan may be responsible for the differences in immune system function against COVID-19. SexH-specific disparities could affect vaccine-related immune response and drug responses in patients with COVID-19. There are many gaps in the knowledge of the exact pathways explaining the association between SexHs and COVID-19 infection. Data on this may improve treatment and prevention modalities and provision of sex-based recommendations with possibly better outcomes.

**Future perspective**

Regarding the concept of multiple roles of SexHs in COVID-19, sex-specified vaccines may be developed in the future. We anticipate that the researchers pay considerable attention to SexH-based modalities in the management of the COVID-19 pandemic. Considering the key role of SexHs in COVID-19, they are suggested as a target for designing SexHs-based interventions.

---

**Executive summary**

- **Sex hormones levels**
  - As a biological factor, the level of sex hormones (SexHs) in males and females may modulate the level of host response.

- **Immunoregulatory effects of SexHs**
  - SexH receptors, as well as testosterone, estradiol and progesterone concentrations may contribute to the immunoregulatory response to COVID-19. A better understanding of this complex pathway offers opportunities to provide better treatment strategies for both males and females.

- **Chromosome-linked genes and SexHs**
  - Sex chromosomes affect SexHs production, and thus, affect angiotensin-converting enzyme 2 and may alter the susceptibility to this infection.

- **Pre-existing disorders and SexHs**
  - Pathological changes in SexHs concentrations may affect the immune response against COVID-19.
Author contributions
All authors contributed in conception, design, drafting of the manuscript and reviewing relevant literature. All authors approved the final version of manuscript.

Acknowledgments
The authors thank all researchers who shared their information aiming to overcome the COVID-19 pandemic.

Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Virayeh Paper Editing Service was utilized in the production of this manuscript.

References
Papers of special note have been highlighted as: ● of interest; ●● of considerable interest
1. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 323(18), 1775–1776 (2020).
2. Meng Y, Wu P, Lu W et al. Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: a retrospective study of 168 severe patients. PLoS Pathog. 16(4), e1008520 (2020).
3. Shim E, Tariq A, Choi W, Lee Y, Chowell G. Transmission potential and severity of COVID-19 in South Korea. Int. J. Infect. Dis. 93, 339–344 (2020).
4. Nasiri MJ, Haddadi S, Tahvildari A et al. COVID-19 clinical characteristics, and sex-specific risk of mortality: systematic review and meta-analysis. Front. Med. 7, 459 (2020).
5. Gadi N, Wu SC, Spihlman AP, Moulton VR. What’s sex got to do with COVID-19? Gender-based differences in the host immune response to coronaviruses. Front. Immunol. 11, 2147 (2020).
6. Jin J-M, Bai P, He W et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front. Public Health 8, 152 (2020).
7. Pradhan A, Olsson P-E. Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biol. Sex Differ. 11(1), 1–11 (2020).
8. Acheampong DO, Barflour IK, Boye A, Aninagyei E, Ocansey S, Morna MT. Male predisposition to severe COVID-19: review of evidence and potential therapeutic prospects. Biomed. Pharmacother. 131, 110748 (2020).
9. Kadel S, Kovats S. Sex hormones regulate innate immune cells and promote sex differences in respiratory virus infection. Front. Immunol. 9, 1653 (2018).
10. Mauvais-Jarvis F, Bairey Merz N, Barnes PJ et al. Sex and gender: modifiers of health, disease, and medicine. Lancet 396(10250), 565–582 (2020).
11. Westergaard D, Moseley P, Sørup FKH, Baldi P, Brunak S. Population-wide analysis of differences in disease progression patterns in men and women. Nat. Commun. 10(1), 666 (2019).
12. Vlassoff C. Gender differences in determinants and consequences of health and illness. J. Health Popul. Nutr. 25(1), 47–61 (2007).
13. Verthelyi D. Sex hormones as immunomodulators in health and disease. Int. Immunopharmacol. 1(6), 983–993 (2001).
14. Klein SL. The effects of hormones on sex differences in infection: from genes to behavior. Neurosci. Biobehav. Rev. 24(6), 627–638 (2000).
15. Hoffmann M, Kleine-Weber H, Schroeder S et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2), 271–280.e278 (2020).
16. Mjaess G, Karam A, Aoun F, Albisinni S, Roumeguère T. COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor. Prog. Urol. 30(10), 484–487 (2020).
17. Foresta C, Rocca MS, Di Nisio A. Gender susceptibility to COVID-19: a review of the putative role of sex hormones and X chromosome. J. Endocrinol. Invest. 6, 1–6 (2020).
18. Taneja V. Sex hormones determine immune response. Front. Immunol. 9, 1931–1931 (2018).
19. Majdic G. Could sex/gender differences in ACE2 expression in the lungs contribute to the large gender disparity in the morbidity and mortality of patients infected with the SARS-CoV-2 virus? Front. Cell. Infect. Microbiol. 10, 327–327 (2020).
20. Grandi G, Facchinetti F, Bitzer J. The gendered impact of coronavirus disease (COVID-19): do estrogens play a role? Eur. J. Contracept. Reprod. Health Care 25(3), 233–234 (2020).
21. Pozzilli P, Lenzi A. Commentary: testosterone, a key hormone in the context of COVID-19 pandemic. *Metab. Clin. Exp.* 108, 154252–154252 (2020).

22. Baethge C, Goldbeck-Wood S, Mertens S. SANRA: a scale for the quality assessment of narrative review articles. *Res. Integr. Peer Rev.* 4(1), 1–7 (2019).

23. Falagas ME, Mourtzoukou EG, Vardakas KZ. Sex differences in the incidence and severity of respiratory tract infections. *Respir. Med.* 101(9), 1845–1863 (2007).

24. Carey MA, Card JW, Volz JW, Germolec DR, Korach KS, Zeldin DC. The impact of sex and sex hormones on lung physiology and disease: lessons from animal studies. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 293(2), L272–278 (2007).

25. Townsend EA, Miller VM, Prakash YS. Sex differences and sex steroids in lung health and disease. *Endocr. Rev.* 33(1), 1–47 (2012).

- Describes the importance of sex steroids in lung health.

26. Klein SL. The effects of hormones on sex differences in infection: from genes to behavior. *Neurosci. Biobehav. Rev.* 24(6), 627–638 (2000).

27. Behan M, Wenninger JM. Sex steroidal hormones and respiratory control. *Respir. Physiol. Neurobiol.* 164(1–2), 213–221 (2008).

28. Ostojic S. *Steroids: From Physiology to Clinical Medicine.* BoD–Books on Demand, IntechOpen (2012).

29. Hammes SR, Levin ER. Impact of estrogens in males and androgens in females. *J. Clin. Invest.* 129(5), 1818–1826 (2019).

30. Brambilla DJ, Matsumoto AM, Araujo AB, Mckinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. *J. Clin. Endocrinol. Metab.* 94(3), 907–913 (2009).

31. O’Donnell L, Stanton P, De Kretser DM. Endocrinology of the male reproductive system and spermatogenesis. In: *Endotext [Internet].* Feingold KR, Anawalt B, Boyce A et al. (Eds). mDT ext.com, Inc., MA, USA (2017).

32. Hess RA. Estrogen in the adult male reproductive tract: a review. *Reprod. Biol. Endocrinol.* 1(1), 52 (2003).

33. Burger HG. Androgen production in women. *Fertil. Steril.* 77, 3–5 (2002).

34. Venkatesh KK, Cu-Uvin S. Anatomic and hormonal changes in the female reproductive tract immune environment during the life cycle: implications for HIV/STI prevention research. *Am. J. Reprod. Immunol.* 71(6), 495–504 (2014).

35. Gubbels Bupp MR, Potthari T, Fink AL, Klein SL. The confluence of sex hormones and aging on immunity. *Front. Immunol.* 9, 1269–1269 (2018).

36. Cattrini C, Bersanelli M, Latocca MM, Conte B, Vallone G, Boccardo F. Sex hormones and hormone therapy during COVID-19 pandemic: implications for patients with cancer. *Cancers* 12(8), 2325 (2020).

- Describes the importance of female SexHs in immune response toward COVID-19.

37. Chen J, Jiang Q, Xia X et al. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. *Aging Cell* 19(7), e13168 (2020).

38. Deng Q, Ur Rasool R, Russell RM, Natesan R, Asangani IA. Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19. *iScience* 24(3), 102254 (2021).

39. Okçülek S. COVID-19 pneumonia causes lower testosterone levels. *Andrologia* 53(1), e13909 (2021).

- Discusses the association between testosterone levels and COVID-19.

40. Muehlenbein MP, Hirschick JL, Bonnet JZ, Swartz AM. Toward quantifying the usage costs of human immunity: altered metabolic rates and hormone levels during acute immune activation in men. *Am. J. Hum. Biol.* 22(4), 546–556 (2010).

41. Kadihasanoglu M, Aktas S, Yardimci E, Aral H, Kadioglu A. SARS-CoV-2 pneumonia affects male reproductive hormone levels: a prospective, cohort study. *J. Sex. Med.* 18(2), 256–264 (2021).

42. Dhindsa S, Zhang N, Mcphaul MJ et al. Association of circulating sex hormones with inflammation and disease severity in patients with COVID-19. *JAMA Netw. Open* 4(5), e2111398–e2111398 (2021).

- Discusses the association between SexHs concentrations and COVID-19 severity.

43. Rastrelli G, Di Stasi V, Inglese F et al. Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. *Andrology* 9(1), 88–98 (2021).

44. Rowland SP, O’Brien Bergin E. Screening for low testosterone is needed for early identification and treatment of men at high risk of mortality from COVID-19. *Crit. Care* 24(1), 367 (2020).

45. Sansone A, Molliäoli D, Ciocca G et al. Addressing male sexual and reproductive health in the wake of COVID-19 outbreak. *J. Endocrinol. Invest.* 44(2), 223–231 (2020).

46. Bianchi VE. The anti-inflammatory effects of testosterone. *J. Endocr. Soc.* 3(1), 91–107 (2019).

47. Auerbach JM, Khera M. Testosterone’s role in COVID-19. *J. Sex. Med.* 18(5), 843–848 (2021).
49. Gorski SA, Hufford MM, Brasciale TJ. Recent insights into pulmonary repair following virus-induced inflammation of the respiratory tract. Curr. Opin. Virol. 2(3), 233–241 (2012).

50. Lai J-J, Lai K-P, Zeng W, Chuang K-H, Altuwaijri S, Chang C. Androgen receptor influences on body defense system via modulation of innate and adaptive immune systems: lessons from conditional AR knockout mice. Am. J. Path. 181(5), 1504–1512 (2012).

51. Provost PR, Blomquist CH, Drolet RE, Flamand N, Tremblay Y. Androgen inactivation in human lung fibroblasts: variations in levels of 17β-hydroxysteroid dehydrogenase type 2 and 5α-reductase activity compatible with androgen inactivation. J. Clin. Endocr. Metab. 87(8), 3883–3892 (2002).

52. Kotfi K, Lechowicz K, Drozdal S et al. Androgens of COVID-19: the potential beneficial therapeutic effects of spironolactone in SARS-CoV-2 infection. Pharmaceuticals (Basel) 14(1), 71 (2021).

■ Describes the importance of potential therapeutic effect of spironolactone in COVID-19.

53. Sultan C, Migeon BR, Rothwell SW, Maes M, Zerhouni N, Migeon CJ. Androgen receptors and metabolism in cultured human fetal fibroblasts. Pediatr. Res. 14(1), 67–69 (1980).

54. Bjørnerem A, Straume B, Oian P, Berntsen GK. Seasonal variation ofestradiol, follicle stimulating hormone, and dehydroepiandrosterone sulfater in women and men. J. Clin. Endocrinol. Metab. 91(10), 3798–3802 (2006).

55. Andersson AM, Carlens E, Petersen JH, Skakkebaek NE. Variation in levels of serum inhibit B, testosterone, estradiol, luteinizing hormone, follicle-stimulating hormone, and sex hormone-binding globulin in monthly samples from healthy men during a 17-month period: possible effects of seasons. J. Clin. Endocrinol. Metab. 88(2), 932–937 (2003).

56. Moyer AM, Matey ET, Miller VM. Individualized medicine: sex, hormones, genetics, and adverse drug reactions. Pharmacol. Res. Perspect. 7(6), e00541–e00541 (2019).

57. Cadegiani FA, Wambier CG, Goren A. Spironolactone: an anti-androgenic and anti-hypertensive drug that may provide protection against the novel coronavirus (SARS-CoV-2) induced acute respiratory distress syndrome (ARDS) in COVID-19. Front. Med. 7, 453 (2020).

58. Cadegiani FA, Goren A, Wambier CG. Spironolactone may provide protection from SARS-CoV-2: targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosteron system (RAAS). Med. Hypothesis 143, 110112 (2020).

59. Mccartney PR. Sex-based vaccine response in the context of COVID-19. J. Obstet. Gynecol. Neonatal Nurs. 49(5), 405–408 (2020).

60. Van Lunzen J, Altfeld M. Sex differences in infectious diseases-common but neglected. J. Infect. Dis. 209(Suppl. 3), 579–580 (2014).

■ Describes the importance of sex differences in infectious diseases.

61. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum. Reprod. Update 11(4), 411–423 (2005).

62. Taneja V. Sex hormones determine immune response. Front. Immunol. 9(1931), 1–5 (2018).

63. Kadel S, Kovats S. Sex hormones regulate innate immune cells and promote sex differences in respiratory virus infection. Front. Immunol. 9, 1653 (2018).

64. Bhatia A, Sekhon HK, Kaur G. Sex hormones and immune dimorphism. Sci. World J. 2014, 159150 (2014).

65. Kovats S. Estrogen receptors regulate innate immune cells and signaling pathways. Cell. Immunol. 294(2), 63–69 (2015).

66. Bird MD, Karavitis J, Kovacs EJ. Sex differences and estrogen modulation of the cellular immune response after injury. Cell. Immunol. 252(1–2), 57–67 (2008).

67. Di Stadio A, Della Volpe A, Ralli M, Ricci G. Gender differences in COVID-19 infection. The estrogen effect on upper and lower airways. Can it help to figure out a treatment? Eur. Rev. Med. Pharmacol. Sci. 24(10), 5195–5196 (2020).

68. Raghavan D, Jain R. Increasing awareness of sex differences in airway diseases. Respir Res 21(3), 449–459 (2016).

69. Lomauro A, Aliveriti A. Sex differences in respiratory function. Breathe (Sheff) 14(2), 131–140 (2018).

70. Beagley KW, Gockel CM. Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEMS Immunol. Med. Microbiol. 38(1), 13–22 (2003).

71. Grimaldi CM, Jeganathan V, Diamond B. Hormonal regulation of B cell development: 17 β-estradiol impairs negative selection of high-affinity DNA-reactive B cells at more than one developmental checkpoint. J. Clin. Endocrinol. Metab. 176(5), 2703–2710 (2006).

72. Salem ML. Estrogen, a double-edged sword: modulation of TH1- and TH2-mediated inflammations by differential regulation of TH1/TH2 cytokine production. Curr. Drug Targets Inflamm. Allergy 3(1), 97–104 (2004).

73. Breithaupt-Faloppa AC, Correia CDJ, Prado CM, Stilhano RS, Ureshino RP, Moreira LFP. 17 β-Estradiol, a potential ally to alleviate SARS-CoV-2 infection. Clinics 75, e1980 (2020).

74. Mccartney PR. Sex-based vaccine response in the context of COVID-19. J. Obstet. Gynecol. Neonatal Nurs. 49(5), 405–408 (2020).

75. Oertelt-Prigione S. Immunology and the menstrual cycle. Autoimmun. Rev. 11(6–7), A486–A492 (2012).

76. Abeggne A, Höggqvist Tabor V. Is female health cyclical? Evolutionary perspectives on menstruation. Trends Ecol. Evol. 33(6), 399–414 (2018).
An overview of sex hormones in relation to SARS-CoV-2 infection

77. Zheng H, Tan J, Ma K, Meng W. Changes in RT-PCR test results and symptoms during the menstrual cycle of female individuals infected with SARS-CoV-2: report of two cases. J. Med. Virol. 93(1), 541–545 (2021).
78. Ding T, Zhang J, Wang T et al. Potential influence of menstrual status and sex hormones on female SARS-CoV-2 infection: a cross-sectional study from multicentre in Wuhan, China. Clin. Infect. Dis. 72(9), e240–e248 (2020).

● Describes the importance of SexHs during COVID-19 pandemic in women.
79. Zhao X, Jiang Y, Zhao Y et al. Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening. Eur. J. Clin. Microbiol. Infect. Dis. 39(7), 1209–1220 (2020).
80. Dasratha P, Wong JJ, Lim MXX et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am. J. Obstet. Gynecol. 222(6), 521–531 (2020).
81. Grandi G, Facchinetti F, Bitzer J. The gendered impact of coronavirus disease (COVID-19): do estrogens play a role? Eur. J. Contracept. Reprod. Health Care 25(3), 233–234 (2020).
82. Fuentes N, Silveira P. Endocrine regulation of lung disease and inflammation. Exp. Biol. Med. (Maywood). 243(17–18), 1313–1322 (2018).
83. Kyrou I, Karteris E, Robbins T, Chatha K, Drenos F, Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic. BMC Med. 18(1), 220 (2020).
84. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Sex. Sex. Differ. 11(1), 1–13 (2020).
85. Trigunaite A, Dimo J, Jørgensen TN. Suppressive effects of androgens on the immune system. Cell. Immunol. 294(2), 87–94 (2015).
86. Takahashi T, Ellington MK, Wong P et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 588(7837), 315–320 (2020).
87. Bharia A, Sekhon HK, Kaur G. Sex hormones and immune dimorphism. Sci. World. J. 2014, 159150 (2014).
88. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annu. Rev. Cell Dev. Biol. 33, 577–599 (2017).
89. Chang W-H. A review of vaccine effects on women in light of the COVID-19 pandemic. Taiwan J. Obstet. Gynecol. 59(6), 812–820 (2020).
90. Kur P, Kolasa-Wobosiak A. Sex hormone-dependent physiology and diseases of liver. Int. J. Environ. Res. Public. Health 17(8), 2620 (2020).
91. Avila M, Bansal A, Culberson J, Peiris AN. The role of sex hormones in multiple sclerosis. Eur. Neurol. 80(1–2), 93–99 (2018).
92. Aloisi AM. Why we still need to speak about sex differences and sex hormones in pain. Pain Ther. 6(2), 111–114 (2017).
93. Bianchi I, Lleo A, Gershwin ME, Invernizzi P. The X chromosome and immune associated genes. J. Autoimmun. 38(2–3), J187–192 (2012).
94. Jing Y, Run-Qian L, Hao-Ran W et al. Potential influence of COVID-19/ACE2 on the female reproductive system. Mol. Hum. Reprod. 26(6), 367–373 (2020).
95. Verma S, Saksena S, Sadri-Ardekani H. ACE2 receptor expression in testes: implications in coronavirus disease 2019 pathogenesis. Biol. Reprod. 103(3), 449–451 (2020).
96. Fan C, Lu W, Li K, Ding Y, Wang J. ACE2 expression in kidney and testis may cause kidney and testis infection in COVID-19 patients. Front. Med. 7(1045), 563893 (2021).
97. Selvaraj K, Ravichandran S, Krishnan S, Radhakrishnan RK, Manickam N, Kandasamy M. Testicular atrophy and hypothalamic pathology in COVID-19: possibility of the incidence of male infertility and HPG axis abnormalities. Reprod. Sci. 7, 1–8 (2021).
98. Shen Q, Xiao X, Aierken A et al. The ACE2 expression in Sertoli cells and germ cells may cause male reproductive disorder after SARS-CoV-2 infection. J. Cell. Mol. Med. 24(16), 9472–9477 (2020).
99. Benetti E, Tiraria P, Spiga O et al. ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. Eur. J. Hum. Genet. 28(11), 1602–1614 (2020).
100. Liu J, Ji H, Zheng W et al. Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are β-oestradiol-dependent and sex chromosome-independent. Biol. Sex Differ. 11(1), 6–6 (2010).
101. Majid G. Could sex/gender differences in ACE2 expression in the lungs contribute to the large gender disparity in the morbidity and mortality of patients infected with the SARS-CoV-2 virus? Front. Cell. Infect. Microbiol. 10(327), 327 (2020).
102. Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tsatis V. COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males? Int. J. Med. Sci. 21(10), 3474 (2020).
103. Manning JT, Fink B. Understanding COVID-19: digit ratio (2D:4D) and sex differences in national case fatality rates. Early Hum. Dev. 146, 105074–105074 (2020).
104. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc. Res. 53(3), 688–708 (2002).
105. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 21(3), 427–433 (2000).
106. Bruns CM, Kemnitz JW. Sex hormones, insulin sensitivity, and diabetes mellitus. ILAR J. 45(2), 160–169 (2004).
107. Shi H, Clegg DJ. Sex differences in the regulation of body weight. Physiol. Behav. 97(2), 199–204 (2009).
108. Karolczak K, Konieczna L, Kostka T et al. Testosterone and dihydrotestosterone reduce platelet activation and reactivity in older men and women. Aging (Albany NY) 10(5), 902–929 (2018).
109. Koupenova M. Potential role of platelets in COVID-19: implications for thrombosis. Res. Pract. Thromb. Haemost. 4(5), 737–740 (2020).
110. Rubinow KB. An intracrine view of sex steroids, immunity, and metabolic regulation. Mol. Metab. 15, 92–103 (2018).
111. Wolff D, Nee S, Hickey NS, Marschollek M. Risk factors for Covid-19 severity and fatality: a structured literature review. Infection 49(1), 15–28 (2021).
112. Williamson EJ, Walker AJ. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584(7821), 430–436 (2020).